---

$17.19

+0.2030 ( +1.20% ) 72.7K

Crescent Biopharma's vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company's pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
No records found.